Squadron Capital Management
Latest statistics and disclosures from Squadron Capital Management's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002050709
Tip: Access up to 7 years of quarterly data
Positions held by Squadron Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Squadron Capital Management
Squadron Capital Management holds 33 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Relmada Therapeutics (RLMD) | 21.6 | $59M | 8.5M | 6.96 |
|
|
| Cogent Biosciences (COGT) | 11.1 | $30M | 788k | 38.49 |
|
|
| Kalvista Pharmaceuticals (KALV) | 9.6 | $26M | 1.3M | 20.13 |
|
|
| Kodiak Sciences (KOD) | 5.3 | $15M | 380k | 38.12 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 5.3 | $15M | 130k | 111.35 |
|
|
| Edgewise Therapeutics (EWTX) | 4.0 | $11M | 350k | 31.50 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 3.5 | $9.4M | 4.0M | 2.34 |
|
|
| Nektar Therapeutics Com New (NKTR) | 3.3 | $9.0M | 125k | 71.95 |
|
|
| Adlai Nortye Sponsored Ads (ANL) | 3.2 | $8.8M | 1.3M | 6.92 |
|
|
| Relay Therapeutics (RLAY) | 3.0 | $8.2M | 823k | 9.95 |
|
|
| Maze Therapeatics (MAZE) | 2.8 | $7.7M | 258k | 29.85 |
|
|
| Ideaya Biosciences (IDYA) | 2.7 | $7.5M | 224k | 33.32 |
|
|
| Scynexis Com New (SCYX) | 2.6 | $7.0M | 7.6M | 0.92 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 2.2 | $5.9M | 2.3M | 2.63 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 2.2 | $5.9M | 3.5M | 1.68 |
|
|
| Palisade Bio (PALI) | 1.9 | $5.3M | 3.0M | 1.75 |
|
|
| Eupraxia Pharmaceuticals (EPRX) | 1.8 | $4.9M | 680k | 7.24 |
|
|
| Gh Research Ordinary Shares (GHRS) | 1.7 | $4.6M | 325k | 14.06 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 1.5 | $4.2M | 750k | 5.57 |
|
|
| Promis Neurosciences Com Shs (PMN) | 1.5 | $4.1M | 325k | 12.70 |
|
|
| Lipocine Com New (LPCN) | 1.3 | $3.6M | 450k | 7.99 |
|
|
| Inventiva Sa Ads (IVA) | 1.1 | $3.0M | 535k | 5.55 |
|
|
| Alx Oncology Hldgs (ALXO) | 1.1 | $2.9M | 1.5M | 2.00 |
|
|
| Context Therapeutics (CNTX) | 1.1 | $2.9M | 1.1M | 2.62 |
|
|
| Nextcure Com New (NXTC) | 1.0 | $2.8M | 265k | 10.68 |
|
|
| Arrivent Biopharma (AVBP) | 0.9 | $2.5M | 110k | 23.07 |
|
|
| Sol-gel Technologies Shs New (SLGL) | 0.9 | $2.5M | 31k | 79.22 |
|
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.6 | $1.6M | 2.1M | 0.74 |
|
|
| Traws Pharma Com New (TRAW) | 0.3 | $936k | 512k | 1.83 |
|
|
| Therapeuticsmd Com New (TXMD) | 0.3 | $849k | 420k | 2.02 |
|
|
| Spruce Biosciences Com New (SPRB) | 0.3 | $797k | 12k | 65.35 |
|
|
| Werewolf Therapeutics (HOWL) | 0.2 | $469k | 564k | 0.83 |
|
|
| Neuphoria Therapeutics (NEUP) | 0.1 | $312k | 77k | 4.07 |
|
Past Filings by Squadron Capital Management
SEC 13F filings are viewable for Squadron Capital Management going back to 2026
- Squadron Capital Management 2026 Q1 filed May 15, 2026